Successfully Transforming From CMO To CDMO

CMOs are now providing more early development support to their customers as well as offering fully integrated services, including specialized services such as aseptic fill-finish. Growth of the full-service contract development and manufacturing organization (CDMO) market has enabled a paradigm shift from early biotechnology companies that wanted to become “fully integrated pharmaceutical companies” to today’s nimble, lean, and sometimes virtual companies.

Visiongain estimates that the global contract pharmaceutical manufacturing market will grow at an average annual rate of 7.5% from $54.54 billion in 2013 to $79.24 billion in 2019.